Adcomm offers mixed vote, recommends GSK's kidney disease drug in just one patient population
A day after the FDA raised safety concerns regarding a kidney disease candidate from GSK, the company did not end up with all green lights …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
